Page last updated: 2024-12-11
papulacandins
Description
papulacandins: isolated from Papularia sphaerosperma (Deutermycetes); see also papulacandin B; structures of papulacandins A,C & D in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
papulacandin : Any of the carbohydrate-containing antibiotic compounds obtained from the deuteromycetous fungus Papularia sphaerosperma and generally consisting of o-orsellinic acid linked via a spirocyclic structure to a lactose moiety with two different side-chains: a shorter fatty-acid chain at the O-(6') position and a longer side-chain at the O-(3) position of the glucose moiety. Papulacandin D, the simplest member of the papulacandin family, lacks the O-(6'-acyl-beta-galactoside) at the O-(4) position of the glucose residue. The papulacandins show potent antifungal activity against Candida albicans, Geotrichum lactis, Saccharomyces cerevisiae, and Pneumocytis carinii, but are inactive against filamentous fungi, bacteria, and protazoa. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 6450326 |
| MeSH ID | M0063504 |
Synonyms (5)
| Synonym |
|---|
| 61036-45-1 |
| papulacandin e |
| papulacandin |
| papulacandins |
| [(3'r,4's,5'r,6'r)-3',4,5',6-tetrahydroxy-6'-(hydroxymethyl)spiro[1h-2-benzofuran-3,2'-oxane]-4'-yl] (2e,4e,8e,10e)-7-hydroxy-8,14-dimethylhexadeca-2,4,8,10-tetraenoate |
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 4 (19.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.37
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.37 (24.57) | | Research Supply Index | 3.09 (2.92) | | Research Growth Index | 4.46 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (4.76%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (95.24%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |